Eagle IP is excited to announce that Jennifer Che, President and Managing Director, will be attending the BIO 2025 International Conference, taking place from June 16-19 at the Boston Convention and Exhibition Centre. Jennifer will be participating in some events together with Hong Kong’s Science and Technology Park (HKSTP), who is hosting the Hong Kong Pavilion at BIO, sending a large delegation of attendees, as well as organizing several events.

This premier biotechnology event attracts over 17,000 professionals from around the globe, featuring networking opportunities, educational sessions, and an exhibition hall showcasing the latest innovations in the industry. Jennifer is looking forward to engaging with fellow attendees and exploring potential collaborations. She invites anyone attending the conference to reach out for a meeting to discuss opportunities, exchange ideas, or simply connect.

About BIO 2025
The BIO International Convention is the world’s largest biotechnology event, providing a platform for networking, learning, and collaboration. Attendees can participate in sessions covering the latest trends, regulatory updates, and scientific advancements, making it an invaluable experience for professionals in the biotech sector.

About Eagle IP
EAGLE IP is a specialized patent firm based in Greater China that facilitates the transfer of new technology from the research environment into the marketplace. Our team of Chinese and US patent practitioners possesses strong cross-border IP knowledge, industry experience, and deep technical expertise. We specialize in China patent strategy, patent drafting and prosecution, patent invalidations, cross-border IP issues, global patent portfolio strategy & management, and Hong Kong patent matters. Our management system is ISO 9001 certified for excellent quality control and management. Should you have any questions, please feel free to contact us at [email protected]

If you won’t be able to attend BIO 2025 but will be in Boston and would like to schedule a meeting, please let us know.

We are looking forward to seeing you in Boston!

我们的过去活动

Recommended Insights

China’s Newest Examination Guidelines: Inventive Step for Biological / Life Science Inventions (Part III)

2021年4月30日
This is Part III of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]

How to Protect a Crystal Form (Polymorph) Patent in China

2025年6月4日
Crystalline forms are critical to pharmaceutical patents, offering extended protection for improved stability, bioavailability, or manufacturability. However, securing such patents in China has grown increasingly difficult due to the China National Intellectual Property Administration (CNIPA)’s strict patentability criteria. Unlike the U.S. or Europe, where structural novelty or problem-solving utility may suffice, China demands quantifiable evidence of […]

AI is magical but NOT magic! Be specific in your AI patents!

2025年1月9日
What is the standard of sufficient disclosure for AI-related patents: A case study in China The rapid growth of AI patent applications present significant challenges to existing patent application and examination practices. One of them is satisfying the requirement for sufficient disclosure. The following case was featured in the 2023 CNIPA Compilation of Key Decisions […]

Narrow Claim Scope of a Chinese Utility Model Patent Fuels Design-Arounds by Failing to Curb Competing Products:

2020年10月28日
Learning from a 2019 China’s Top 50 Representative IP Case The number of patent applications in China is now the highest in the world, with more than half the applications filed as utility model applications (UMs). For example, there were more than 2 million UMs filed in 2018 alone (for the difference between a utility […]
Top crossarrow-right